Balanced news tone
News Sentiment
ABBV sentiment intelligence
AbbVie Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
81/100 classification confidence.
directly relevant articles
high-authority source matches
-5.0% over one week, +8.9% over four weeks, trend active, and materially above fair value.
Is AbbVie (ABBV) Fully Priced Despite Tepkinly Approval And Cash Flow?
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
AbbVie to Acquire Apogee Therapeutics in $10 Billion Deal
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 22 Jun 2026 07:00
- Source
- Pharmaceutical Executive
AbbVie and Merck Face-Off: Which Pharma Stock Has the Lead?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 07:00
- Source
- The Globe and Mail
Why AbbVie Stock Jumped Today
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 07:00
- Source
- Market source
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- Market source
AbbVie (ABBV) Stock Weighs DCF Upside Against Elevated P/E At US$227.73
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 13 Jun 2026 07:00
- Source
- Market source
Is AbbVie Inc. (ABBV) A Good Stock To Buy Now?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 11 Jun 2026 07:00
- Source
- Market source
AbbVie (ABBV) Up 3.5% Since Last Earnings Report: Can It Continue?
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 May 2026 07:00
- Source
- Market source
AbbVie (ABBV) Stock Trades Up, Here Is Why
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Apr 2026 07:00
- Source
- StockStory
AbbVie Invests $1.4 Billion into New Manufacturing Campus in North Carolina
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Apr 2026 07:00
- Source
- Pharmaceutical Executive
AbbVie Q1 Earnings Loom: Buy or Sell the Stock Ahead of Results?
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 23 Apr 2026 07:00
- Source
- TradingView
Haisco Enters $745 Million Exclusive License Agreement with AbbVie
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Apr 2026 07:00
- Source
- Pharmaceutical Executive
AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Apr 2026 07:00
- Source
- StockStory
Pharma Manufacturing Roundup: AbbVie Invests $380 Million to Expand API Manufacturing, Bora Pharmaceuticals and GSK Enters Five Year Manufacturing Agreement
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Feb 2026 08:00
- Source
- Pharmaceutical Executive
AbbVie’s $380M Illinois build to add 300 jobs, boost obesity drugs
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Feb 2026 08:00
- Source
- Stock Titan
AbbVie Joins Trump Drug Pricing Effort, Pledges $100B in US R&D Investment
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jan 2026 08:00
- Source
- The American Journal of Managed Care® (AJMC®)